Table 1 Baseline Characteristics of Patients Undergoing Prevalent Dialysis.

From: The Optimal Blood Pressure Target in Different Dialysis Populations

 

Total (n = 2,299)

Distribution of SBP (mmHg)

<110 (n = 158)

110–119 (N = 202)

120–129 (N = 370)

130–139 (n = 492)

140–149 (n = 423)

150–159 (n = 296)

160–169 (n = 176)

≥170 (n = 182)

P

Age (years)

62.3 ± 13.0

61.9 ± 13.2

62.8 ± 13.3

61.6 ± 13.2

61.9 ± 12.8

63.0 ± 13.1

62.3 ± 12.9

62.8 ± 12.8

62.0 ± 13.0

0.91

Male (%)

1,306 (56.8)

75 (47.5)

105 (52.0)

204 (55.1)

288 (58.5)

254 (60.0)

173 (58.4)

104 (59.1)

103 (56.6)

0.37

Body mass index (kg/m2)

22.8 ± 3.3

22.2 ± 3.1

22.8 ± 3.4

22.7 ± 3.3

23.1 ± 3.4

23.0 ± 3.3

22.6 ± 33.4

22.8 ± 3.4

22.4 ± 3.2

0.07

Hemodialysis (%)

1,375 (59.9)

67 (42.4)

102 (50.7)

203 (54.9)

274 (56.0)

268 (63.4)

205 (69.5)

129 (73.3)

127 (69.8)

<0.001

Dialysis vintage (years)

8.7 ± 4.5

9.6 ± 5.2

8.2 ± 4.3

8.9 ± 4.8

8.6 ± 4.5

8.5 ± 4.5

9.0 ± 4.5

8.6 ± 4.4

8.7 ± 3.7

0.12

Kt/V

Hemodialysis

1.4 ± 0.5

1.5 ± 0.6

1.5 ± 0.4

1.4 ± 0.5

1.4 ± 0.5

1.4 ± 0.5

1.5 ± 0.7

1.4 ± 0.4

1.4 ± 0.3

0.54

Peritoneal Dialysis

1.5 ± 0.5

1.5 ± 0.6

1.8 ± 0.2

1.4 ± 0.6

1.5 ± 0.6

1.5 ± 0.9

1.4 ± 0.4

1.5 ± 0.5

1.5 ± 0.4

0.05

Number of AHAs

1.9 ± 1.4

1.3 ± 1.4

1.6 ± 1.4

1.8 ± 1.5

1.9 ± 1.4

2.1 ± 1.4

2.2 ± 1.4

2.3 ± 1.3

2.4 ± 1.3

<0.001

Classes of AHAs

ACEi/ARBs

1,271 (55.3)

65 (41.1)

106 (52.5)

189 (51.1)

258 (52.4)

237 (56.0)

179 (60.5)

115 (65.3)

122 (67.0)

<0.001

CCBs

1,167 (50.8)

45 (28.5)

81 (40.1)

164 (44.3)

247 (50.2)

231 (54.6)

177 (59.8)

113 (64.2)

109 (59.9)

<0.001

BBs

1,085 (47.2)

45 (28.5)

76 (37.6)

159 (43.0)

220 (44.7)

207 (48.9)

162 (54.7)

102 (58.0)

114 (62.6)

<0.001

alpha-blockers

246 (10.7)

6 (3.8)

12 (5.9)

40 (10.8)

55 (11.2)

53 (12.5)

39 (13.2)

18 (10.2)

23 (12.6)

0.02

Comorbidities

DM (%)

730 (31.8)

48 (30.4)

49 (24.3)

94 (25.4)

150 (30.5)

152 (35.9)

87 (29.4)

73 (41.5)

77 (42.3)

0.001

CVD (%)

336 (14.6)

32 (20.3)

29 914.4)

60 (16.2)

70 (14.2)

54 (12.8)

40 (13.5)

29 (16.5)

22 (12.1)

0.36

Stroke (%)

30 (1.3)

4 (2.5)

2 (1.0)

3 (0.8)

10 (2.0)

5 (1.2)

2 (0.7)

3 (1.7)

1 (0.5)

0.46

Laboratory data

Hemoglobin (g/dL)

10.7 ± 3.9

10.8 ± 1.6

10.6 ± 1.2

10.8 ± 1.3

10.6 ± 1.3

11.0 ± 5.6

11.0 ± 5.8

10.3 ± 1.2

10.7 ± 7.1

0.58

Albumin (g/dL)

33.9 ± 1.4

4.0 ± 2.7

3.8 ± 0.4

3.8 ± 0.4

3.9 ± 1.9

3.9 ± 1.7

3.8 ± 0.4

3.8 ± 0.4

3.7 ± 0.5

0.81

Total cholesterol (mg/dL)

162.4 ± 39.6

162.2 ± 39.8

166.7 ± 39.6

165.5 ± 40.1

166.3 ± 41.7

161.3 ± 38.6

159.0 ± 38.3

154.7 ± 35.7

156.9 ± 38.5

0.003

LDL-C (mg/dL)

92.0 ± 32.8

91.6 ± 29.5

96.5 ± 35.8

93.1 ± 32.0

96.0 ± 35.8

92.5 ± 33.2

87.4 ± 31.6

84.5 ± 27.9

90.1 ± 29.9

0.003

HbA1c (%)

6.5 ± 1.7

6.3 ± 1.6

6.2 ± 1.2

6.2 ± 1.4

6.4 ± 2.0

6.6 ± 1.7

6.6 ± 1.9

6.6 ± 1.6

6.6 ± 1.8

0.19

Sodium (mmol/L)

137.7 ± 6.0

137.6 ± 4.1

137.2 ± 10.2

138.3 ± 3.2

138.1 ± 3.5

137.7 ± 3.8

137.3 ± 8.6

136.8 ± 3.8

137.0 ± 10.2

0.03

Bicarbonate (mmol/L)

23.7 ± 8.6

24.2 ± 3.8

24.8 ± 11.2

24.1 ± 15.4

24.1 ± 4.0

23.4 ± 5.6

23.5 ± 9.5

22.0 ± 3.5

23.1 ± 4.4

0.28

Ferritin (ng/mL)a

203.2 [101.0–382.3]

224.7 [79.7–405.3]

205.2 [109.6–367.7]

199.8 [94.0–373.0]

192.9 [96.5–391.7]

200.6 [98.8–372.1]

179.3 [101.8–332.2]

213.6 [115.0–370.3]

246.6 [129.1–429.5]

0.38

hs-CRP a(mg/dL)

0.13 [0.02–0.55]

0.14 [0.04–0.51]

0.11 [0.01–0.59]

0.12 [0.02–0.39]

0.13 [0.02–0.68]

0.12 [0.02–0.52]

0.17 [0.01–0.58]

0.17 [0.04–0.72]

0.12 [0.01–0.61]

0.66

  1. Note: aKruskal-Wallis test.
  2. Abbreviations: AHA, antihypertensive agent; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; BB, beta-blocker; DM, diabetes mellitus; CHF, congestive heart failure; CVD, cardiovascular disease; LDL-C, low-density lipoprotein-cholesterol; hs-CRP, high-sensitivity C-reactive protein.